FCM
TBIO

Farallon Capital Management’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

Farallon Capital Management’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-100,000
Closed -$1.02M – 110
2019
Q1 		$1.02M Sell
100,000
-400,000
-80% -$3.07M 0.01% 94
2018
Q4 		$3.75M Buy
500,000
+50,000
+11% +$366K 0.03% 89
2018
Q3 		$4.5M Buy
450,000
+50,000
+13% +$582K 0.03% 90
2018
Q2 		$5.06M Buy
+400,000
New +$4.83M 0.03% 85

Other funds holding TBIO

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Farallon Capital Management's TBIO Position: Q2 2019 in Review

Farallon Capital Management sold out of Translate Bio, Inc. Common Stock (TBIO) in Q2 2019, closing a stake of 100,000 shares — an estimated $1.02M sold.

Farallon Capital Management first reported a position in TBIO in Q2 2018 and held it in 4 quarters. The position peaked at $5.06M in Q2 2018. 60 funds tracked by Wall St. Rank hold TBIO as of Q2 2019.

  • Farallon Capital Management reported no remaining Translate Bio, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Farallon Capital Management sold 100,000 Translate Bio, Inc. Common Stock shares in Q2 2019, an estimated $1.02M.
  • Farallon Capital Management first reported a position in Translate Bio, Inc. Common Stock in Q2 2018 and held it in 4 quarters.
  • Farallon Capital Management's Translate Bio, Inc. Common Stock position peaked at $5.06M in Q2 2018.
  • 60 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q2 2019.

Based on Farallon Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.